2 completed, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow Tricuspid Regurgitation: new trials by email Literature Review of Tricuspid Regurgitation trials Research Report on Tricuspid Regurgitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Enavogliflozin, Placebo - Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction | Phase 3 | Active not recruiting | Asan Medical Center | 541 | 2023-10-25 | 2025-12-29 |
| Pharmacological Reduction of Right Ventricular Enlargement Carvedilol+Empagliflozin, Carvedilol, Empagliflozin - Tricuspid Regurgitation, Right Ventricular Dilatation | Phase 3 | Completed | Asan Medical Center | 56 | 2021-02-15 | 2025-04-06 |
| Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER) Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava - Tricuspid Regurgitation | Phase 3 | Completed | Henry Ford Health System | 15 | 2015-01-01 | 2025-06-18 |
Tricuspid Valve Insufficiency (3)
Cardiovascular Diseases (3) · Heart Diseases (3) · Heart Valve Diseases (3)
Carvedilol (1) · Enavogliflozin (1) · empagliflozin (1)
Asan Medical Center (2) · Henry Ford Health System (1)
South Korea (2) · United States (1)